Clinical Trial Update: A Study of Acalabrutinib in Combination With Rituximab Versus Ibrutinib Versus Acalabrutinib in Subjects With Relapsed or Refractory Mantle Cell Lymphoma [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating acalabrutinib in combination with rituximab versus ibrutinib versus acalabrutinib in relapsed or refractory mantle cell lymphoma has …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Mantle Cell Lymphoma

Drugs mentioned

• CALQUENCE (ACALABRUTINIB)
• IMBRUVICA (IBRUTINIB)
• Rituxan (rituximab)

Snippet

Sponsor: Acerta Pharma BV | Conditions: Mantle Cell Lymphoma | Phase 3 | Status: WITHDRAWN